Skip to main content
OpenTrials
Completed

NCT Number: NCT01073904

Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg

A single dose, two treatments (Postinor-2 and Opxion), two periods, two sequences, crossover, randomized, prospective design was chosen with a washout of 14 days between the two study periods. Treatment groups are balanced with the same number of male healthy volunteers who were randomly assigned to the study drug administration sequences.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Contraceptives, Postcoital

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Morelia, Michoacán, 58256, Mexico

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male volunteers age between 18 and 55 years old with normal vital signs, electrocardiogram (ECG), blood chemistry, liver function profile and urinalysis.

Exclusion criteria

  • History of illnesses or any organic abnormalities that could affect the results of the study.
  • History of tobacco or alcohol abuse or regular use of recreational or therapeutic drugs.
  • Subjects that have taken any medication within 14 days or that are in an elimination period of less than 7 half-lives (whichever is longest) before study startup.

Treatment and study plan

Levonorgestrel Emergency Pill (BAY86-5028)

Drug

Single dose of 1.5 mg coated tablet

Postinor 2

Drug

Single dose of 1.5 mg tablet

Primary outcomes

  1. Least square estimator of average maximum plasmatic concentration (log transformed)

    Time frame: After 2 months

  2. Least square estimator of area under the pharmacokinetic curve (log transformed)

    Time frame: After 2 months

Secondary outcomes

  1. Time at which maximum concentration is reached

    Time frame: After 2 months

  2. Area under the pharmacokinetic curve from time=0 to last blood sample

    Time frame: After 2 months

  3. Half life of plasmatic concentration of study drug

    Time frame: After 2 months

  4. Clearance constant of plasmatic concentration of study drug

    Time frame: After 2 months

  5. Adverse events collection

    Time frame: Up to 8 weeks

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Open-label, Randomized, Crossover Study to Prove the Bioequivalence Between Opxion® (Levonorgestrel 1.5 mg Coated Tablet From Bayer de Mexico) and Postinor 2® (Levonorgestrel 1.5 mg Tablet From Biofarma Natural CMD) in Healthy Volunteers

Acronym: LEVEQ-3

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Feb 23, 2010
Registry last updated
Apr 3, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.